Effect of dose schedule using Ranibizumab and Verteporfin in Japanese Polypoidal Choroidal Vasculopathy Patients (Fuji-san study)

Effect of dose schedule using Ranibizumab and Verteporfin in Japanese Polypoidal Choroidal Vasculopathy Patients (Fuji-san study) - Dose schedule of verteporfin and ranibizumab in Japanese polypoidal choroidal vasculopathy patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004845

Enrollment

Registered

2011-01-08

Start date

2011-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polypoidal Choroidal Vasculopathy

Interventions

Ranibizumab preceding its combined treatment with verteporfin photodynamic therapy Ranibizumab combined with verteporfin photodynamic therapy

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Treatment naive, typical PCV according to the diagnostic criteria of of the PCV Study Group in Japan 2. Subfoveal hemorrhage or fluid 3. Greatest Linear Dimension (GLD) of the total lesion area <6231 micron(<12 Macular Photocoagulation Study Disc Areas) determined on ICG angiography 4. Decimal BCVA between 0.1-0.7. Male patients, and 50 yrs of age 6. Patients must give written informed consent before any assessment is performed.

Exclusion criteria

Exclusion criteria: 1.Histories of prior treatments for PCV 2.Hypersensitivity or allergy to fluorescein or indocyanine green (ICG), clinically significant drug allergy or known hypersensitivity to therapeutic or diagnostic protein products, or to any of the study drugs or their components 3.Patient with history of porphyria 4.Histories of which might affect the interpretation of the results of the study, or renders the patient at high risk from treatment complications 5.Presence of RPE tears, angioid streaks, macular fibrosis, pathologic myopia (-6 diopters or more) , central serous chorioretinopathy 6.Concomitant conditions/diseases in study eyes including uncontrolled glaucoma and active ocular inflammation 7.Intraocular surgery within 2 months 8.Presence of typical type 2 CNV

Design outcomes

Primary

Measure	Time frame
Best corrected visual acuity at 12 month	—

Countries

Japan

Contacts

Public ContactFumi Gomi

Osaka University, Graduate School of Medicine Department of Ophthalmology

fgomi@ophthal.med.osaka-u.ac.jp06-6879-3456

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026